Since mHAdLyp.sT inhibits the TGFβ signaling pathway, a combination therapy with immune checkpoint inhibitors could more effectively inhibit MDSCs related immune suppression, both systemically and in the tumor. Here, TGFB1 is linked to neoplasm.